PROTAC GDI2 Degrader-1

PROTAC GDI2 Degrader-1

• UNSPSC Description: PROTAC GDI2 Degrader-1 (compound 21) is a potent PROTAC GDI2 degrader. PROTAC GDI2 Degrader-1 exhibits excellent in vivo antitumor activity in the GDI2-overexpressing pancreatic xenograft models[1].
• Target Antigen: PROTACs
• Type: Reference compound
• Related Pathways: PROTAC
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/protac-gdi2-degrader-1.html
• Solubility: 10 mM in DMSO
• Smiles: CC1=CC(C)=CC(COC2=CC3=C([C@](C[C@](O)(CC4=CN(CCOCCOCCOCCNC([C@@H](CC(C)C)NC([C@@H](O)[C@H](N)CC5=CC=CC=C5)=O)=O)N=N4)C[C@@H]6C)([H])N6CC3)C=C2OCC7=CC(C)=CC(C)=C7)=C1
• Molecular Weight: 1032.32
• References & Citations: [1]Yong Sun, et al. Targeting GDP-Dissociation Inhibitor Beta (GDI2) with a Benzo[a]quinolizidine Library to Induce Paraptosis for Cancer Therapy. JACS Au 2023, September 26, 2023
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported